SHTDY (Sinopharm Group Co) Beginning Cash Position: $5,003 Mil (As of Dec. 2025)


SHTDY Sinopharm Group Co Ltd SHTDY
73 GF Score
Price $10.65
GF Value $13.29
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Beginning Cash Position?

Sinopharm Group Co SHTDY -0.28% 73 Beginning Cash Position is $5,003 Mil as of Dec. 2025. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.29 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sinopharm Group Co's Beginning Cash Position for the quarter that ended in Dec. 2025 was $5,003 Mil.

Sinopharm Group Co's quarterly Beginning Cash Position increased from Dec. 2024 ($5,952 Mil) to Jun. 2025 ($7,564 Mil) but then declined from Jun. 2025 ($7,564 Mil) to Dec. 2025 ($5,003 Mil).

Sinopharm Group Co's annual Beginning Cash Position increased from Dec. 2023 ($7,734 Mil) to Dec. 2024 ($8,764 Mil) but then declined from Dec. 2024 ($8,764 Mil) to Dec. 2025 ($7,711 Mil).

Sinopharm Group Co Beginning Cash Position Related Terms

Sinopharm Group Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Beginning Cash Position Chart

Sinopharm Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,878.15 6,243.73 7,733.90 8,764.07 7,711.46

Sinopharm Group Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,814.59 8,795.48 5,951.59 7,564.11 5,003.14
SHTDY
73GF Score
Sinopharm Group Co Ltd SHTDY
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $5,003 Mil mean?
Sinopharm Group Co (SHTDY) has a Beginning Cash Position of $5,003 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Beginning Cash Position too high?
Sinopharm Group Co's current Beginning Cash Position is $5,003 Mil. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Beginning Cash Position compare to MCK and CAH?
Sinopharm Group Co's Beginning Cash Position of $5,003 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Distribution company?
A good Beginning Cash Position depends on the Medical Distribution industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Beginning Cash Position is $5,003 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.29, compared to a current price of $10.65 — trading 19.9% below its estimated fair value. The current Beginning Cash Position is $5,003 Mil. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Beginning Cash Position is $5,003 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDY) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $10.65 is trading 19.9% below its estimated GF Value™ of $13.29. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDY:

  • Beginning Cash Position: $5,003 Mil
  • GF Value™: $13.29 vs. price of $10.65 (19.9% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score

Get the complete analysis for SHTDY

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.65
Price
$13.29
GF Value